The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An 11-gene expression signature related to tumorigenesis and immunosuppression in primary cutaneous melanoma predicts sentinel lymph node metastatic status.
 
Ahmad A. Tarhini
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Clinigen Group; Eisai; Genentech/Roche; Instil Bio; Merck; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst)
 
Brian Hobbs
Stock and Other Ownership Interests - Telperian
Consulting or Advisory Role - Amgen; Bayer; STCube Pharmaceuticals Inc.
Research Funding - Amgen
 
Arjun Khunger
No Relationships to Disclose
 
Ibrahim Yassine
No Relationships to Disclose
 
Iyad Kobeissi
No Relationships to Disclose
 
Patrick Hwu
Stock and Other Ownership Interests - Dragonfly Therapeutics; Immatics
Consulting or Advisory Role - Dragonfly Therapeutics; Immatics
Research Funding - Genentech (Inst)
 
Vernon K. Sondak
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck/Schering Plough; Novartis; Regeneron
Research Funding - Neogene Therapeutics (Inst); Turnstone Bio (Inst)
 
William LaFramboise
Stock and Other Ownership Interests - Prevencio
Patents, Royalties, Other Intellectual Property - Patents associated with the technology utilized by Prevencio.
 
John M. Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; Ankyra Therapeutics; AXIO Research; Becker Pharmaceutical Consulting; Checkmate Pharmaceuticals; DermTech; Fenix Group International; Harbour BioMed; Immunocore; Intellisphere, LLC; Iovance Biotherapeutics; IQVIA; Istari Oncology; Merck; Natera; Novartis; Oncocyte; OncoSec; Pfizer; Replimune; Scopus BioPharma; SR One Capital Management; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst); Schering-Plough (Inst); Takeda (Inst); Verastem (Inst)